Evidence map›Paper›PMID 40734859›Full record

ReviewCureus2025

Pharmacovigilance in the Era of Artificial Intelligence: Advancements, Challenges, and Considerations.

Eli Rudnisky, Keshab Paudel

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eli RudniskyBiomedical Sciences, Burrell College of Osteopathic Medicine, Melbourne, USA.
Keshab PaudelBiomedical Sciences, Burrell College of Osteopathic Medicine, Melbourne, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacovigilance (PV) is a science that plays a crucial role in protecting patients by detecting adverse drug reactions (ADRs). PV can do this by collecting and analyzing data from a wide variety of healthcare sources. However, traditional PV methods face limitations, particularly in accurately and efficiently analyzing large datasets. This limitation leads to underreported ADRs, which negatively impact many patients. However, with the recent rise in artificial intelligence, PV as a science has the potential to improve. This can be done by incorporating different subsets of AI, such as machine learning (ML) and natural language processing (NLP), into PV. The aim of this study is to describe how integrating AI, specifically ML and NLP, into PV systems can improve data collection, data processing, and the detection of ADRs. A comprehensive literature search was conducted using PubMed and Google Scholar to examine studies that were conducted within the last 30 years. Twenty-eight studies were included in this paper. Inclusion criteria included articles that were written in English, articles focusing on PV as a science, ADRs, AI's current role in PV, and AI's potential role in PV. Exclusion criteria included studies that were not published in English and studies that were published more than 30 years ago. The findings from several systematic reviews that explore the implementation of AI into PV indicate that AI can improve PV by enhancing the efficiency and accuracy of detecting ADRs. Through ML algorithms, ADRs can be identified more quickly and accurately compared to traditional PV methods; while using the NLP model, AI is able to extract relevant patient data from unstructured data sources such as electronic health records (EHRs) and report certain drug interactions more accurately and efficiently. However, there are limitations to incorporating AI into PV. These include ethical, legal, and privacy concerns; interpretative limitations if certain datasets are incomplete and are missing information; the lack of current research; and the need to conduct more research on this topic to definitively determine whether AI should be incorporated into PV. With the exponential development of technology such as AI, there is a lot of promise in strengthening PV into a more accurate and efficient ADR detection system. While there is some research highlighting AI's potential to enhance PV, much more research needs to be conducted to fully substantiate this claim. Incorporating AI into PV does, however, have the potential to change ADR detection methods for the better.

Indexed as

adverse drug reactions (adr)ai and machine learningartificial intelligence in medicinenatural language processing (nlp)pharmacovigilance

Identifiers

PMID40734859
PMCPMC12306650

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.